Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 19393267
Shin MS, et al. (2009) Cross interference with TNF-alpha-induced TAK1 activation via EGFR-mediated p38 phosphorylation of TAK1-binding protein 1. Biochim Biophys Acta 1793, 1156-64 19393267
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S536-p - NFkB-p65 (human)
Modsite: sGDEDFSsIADMDFS SwissProt Entrez-Gene
Orthologous residues
NFkB‑p65 (human): S536‑p, NFkB‑p65 (mouse): S534‑p, NFkB‑p65 (rat): S535‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  phosphorylation of this site is negatively regulated by p38-alpha mediated phosphorylation of TAB1 S423 and T431
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
EGF TNF inhibit treatment-induced increase

S423-p - TAB1 (human)
Modsite: QMVNGAHsASTLDEA SwissProt Entrez-Gene
Orthologous residues
TAB1 (human): S423‑p, TAB1 iso2 (human): S423‑p, TAB1 (mouse): S421‑p, TAB1 (rat): S421‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE P38A (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
SB203580 EGF inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  phosphorylation
Comments:  inhibits TAK1 T187 phosphorylation

T431-p - TAB1 (human)
Modsite: ASTLDEAtPTLTNQs SwissProt Entrez-Gene
Orthologous residues
TAB1 (human): T431‑p, TAB1 iso2 (human): T431‑p, TAB1 (mouse): T429‑p, TAB1 (rat): T429‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE P38A (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
SB203580 EGF inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  phosphorylation
Comments:  inhibits TAK1 T187 phosphorylation

S438-p - TAB1 (human)
Modsite: tPTLTNQsPTLtLQS SwissProt Entrez-Gene
Orthologous residues
TAB1 (human): S438‑p, TAB1 iso2 (human): P438‑p, TAB1 (mouse): S436‑p, TAB1 (rat): S436‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Downstream Regulation
Effect of modification (function):  phosphorylation
Comments:  inhibits TAK1 T187 phosphorylation

T187-p - TAK1 (human)
Modsite: CDIQtHMtNNKGsAA SwissProt Entrez-Gene
Orthologous residues
TAK1 (human): T187‑p, TAK1 (mouse): T187‑p, TAK1 iso3 (mouse): T187‑p, TAK1 (rat): T187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  phosphorylation of this site is negatively regulated by p38-alpha mediated phosphorylation of TAB1 S423 and T431
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
EGF TNF inhibit treatment-induced increase
siRNA EGF, TNF inhibit treatment-induced decrease against p38-alpha
SB203580 EGF, TNF inhibit treatment-induced decrease
anisomycin TNF inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced